Aclaris Therapeutics, Inc. (ACRS)

Over the past six months, Aclaris Therapeutics' stock has increased by 82.80%. As of March 25, 2026, the stock price was $3.59 per share, a 121.60% increase from March 27, 2025. Key events include being added to the Nasdaq Biotechnology Index in December 2025, positive interim results from the Phase 1a trial of ATI-052 in January 2026, and Q4 2025 earnings reported in February 2026 with an EPS miss. In March 2026, results were presented at the AAD Annual Meeting, enrollment in the Phase 2 trial of Bosakitug was completed, and analyst ratings included Wedbush and HC Wainwright & Co. reiterating positive ratings.

The provided search results do not contain specific information regarding demand seasonality for Aclaris Therapeutics, Inc.'s products and services. As a clinical-stage biopharmaceutical company, its revenue streams are primarily tied to research and development activities, milestones, and potential future commercialization, rather than seasonal consumer demand for established products.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel drug candidates for immuno-inflammatory diseases. The company operates in the healthcare sector, specifically in drug discovery and biotechnology. Aclaris uses its KINect® drug discovery platform to create new small molecule medicines through kinome innovation, focusing on kinase inhibitors that target enzymes involved in chronic inflammation, autoimmune disease, and cancer. The company operates through Therapeutics and Contract Research segments. Its pipeline includes Zunsemetinib (ATI-450), Bosakitug (ATI-045), ATI-2138, ATI-052, ATI-9494, and Lepzacitinib (ATI-1777).

Aclaris Therapeutics, Inc. is headquartered in Wayne, Pennsylvania, United States. Its operations are primarily conducted in the United States. Its subsidiary, Confluence Discovery Technologies, Inc., is located in Saint Louis, MO. Aclaris Therapeutics International Limited is incorporated in the United Kingdom.

Information directly detailing Aclaris Therapeutics' brand reputation is not explicitly available. Positive events that could contribute to a favorable reputation include positive interim results from the Phase 1a trial of ATI-052, positive Phase 2a trial results for ATI-2138, completion of enrollment in the Phase 2 trial of Bosakitug, inclusion in the Nasdaq Biotechnology Index, and a consensus "Moderate Buy" rating from analysts. The company's Q4 2025 earnings miss could be a minor negative factor.

Aclaris Therapeutics, Inc. has a mixed ownership structure including institutional, retail, and individual investors. Institutional investors hold a significant portion, approximately 57.14% or 59%. Insiders own about 2.70% of the company's stock, with CEO Neal Walker directly holding 1.4% of the total shares outstanding. Major institutional owners include BML Capital Management, LLC, Vivo Capital, LLC, and BlackRock, Inc.